Application of reagent for detecting expression quantity of biomarker in preparation of product for evaluating prognosis of kidney cancer and kit for evaluating prognosis of kidney cancer

By detecting the expression of specific genes in patients with renal cancer, the problem of insufficient evaluation of renal cancer prognostic risk and immunotherapy effects in the prior art is solved, and the guidance of accurate diagnosis and treatment strategies for patients with renal cancer is achieved, and the patient's Survival and disease management.

CN119020490APending Publication Date: 2024-11-26PEKING UNIVERSITY SHENZHEN HOSPITAL
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411107197.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art is difficult to effectively evaluate the prognostic risks and benefits of immunotherapy in patients with renal cancer. Traditional pathological histological typing is not enough to assist in clinical accurate diagnosis and treatment screening. The drug resistance of targeted drugs is serious, resulting in limited treatment effect.

Method used

The mRNA and protein levels of genes such as FOS, JUNB, EGR1, NR4A1, IER2, ATF3 were detected by fluorescence quantitative PCR and immunohistochemistry, and SLC16A9, SLC13A1, CYP4A11 were screened out. The expression of genes such as ESRRG is used to evaluate the prognosis of patients with renal cancer.

Benefits of technology

Through integrated multiomic analysis, prognostic markers are screened out to help judge the prognosis of renal cancer patients, guide accurate treatment strategies, and improve patients' survival and disease management.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020490A_ABST
    Figure CN119020490A_ABST
Patent Text Reader

Abstract

The invention discloses an application of a reagent for detecting the expression quantity of a biomarker in preparation of a product for evaluating the prognosis of kidney cancer and a kit for evaluating the prognosis of kidney cancer, the expression quantity comprises the expression quantity of mRNA level and protein level, and the biomarker comprises a first biomarker and / or a second biomarker, the first biomarker comprises the following genes: FOS, JUNB, EGR1, NR4A1, IER2 and ATF3, and the second biomarker comprises at least one of the following genes: SLC16A9, SLC13A1, CYP4A11 and ESRRG. According to the application, multiple omics analysis means are integrated, the prognosis marker, namely the biomarker, of the kidney cancer is screened and identified, and the prognosis of a kidney cancer patient can be judged by detecting the biomarker, so that accurate treatment and whole-course disease management are facilitated, and the survival of the patient is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biotechnology, and in particular to an application of a reagent for detecting the expression amount of a biomarker in the preparation of a product for evaluating the prognosis of renal cancer, and a kit for evaluating the prognosis of renal cancer. Background Art

[0002] Malignant tumors seriously threaten human life and health. Renal cancer, as one of the most malignant kidney diseases, is the malignant tumor with the highest mortality rate in the urinary system. Among them, clear cell renal cell carcinoma (ccRCC) is the most common pathological type of renal cancer, accounting for about 75% of the total number of renal cancers. Postoperative resection specimen pathology is the gold standard for diagnosing ccRCC. ccRCC is insensitive to traditional radiotherapy and chemotherapy. Surgery is the most important method for treating early localized ccRCC. However, up to 30% of patients will experience recurrence or distant metastasis after complete tumor resection. Once metastasis occurs, the patient's survival rate will drop sharply from more than 50% to 12%. In recent years, with the development of targeted drugs and immunotherapy, the overall treatment effect and prognosis of patients with advanced metastatic ccRCC have been improved, such as vascular endothelial growth factor (VEGF) inhibitors, including sunitinib, pazopanib, axitinib and cabozantinib; mammalian target of rapamycin (mTOR) inhibitors, including everolimus and temsirolimus; and immune checkpoint inhibitors PD-1 / PD-L1 inhibitors and CTLA-4 inhibitors. However, a considerable number of patients do not benefit from targeted or immunotherapy, and about 30% of patients will develop primary or secondary drug resistance. It can be seen that renal cancer treatment still faces huge challenges. Traditional pathological histological typing is not enough to assist clinical effective prognostic evaluation, treatment screening and full-course management. There is still a lack of effective stratification indicators for different prognostic risks and immunotherapy benefit populations in the clinic. Even ccRCC patients with the same or similar pathological typing and staging grades have great differences in drug sensitivity and metastasis risk. Therefore, under the precision medicine model, further classifying and diagnosing the disease based on the molecular characteristics of ccRCC and tailoring personalized adjuvant treatment and clinical monitoring plans for patients are effective ways to improve patient prognosis and survival.

[0003] However, tumor heterogeneity poses a huge challenge to the precise diagnosis and treatment of tumors. Tumor heterogeneity refers to the differences in genotype and phenotype of the same malignant tumor, which are manifested in two aspects: first, the differences between different patients. This can be attributed to the differences in genetic background between patients, as well as the diversity of tumor evolution caused by differences in tumor tissue pathology, clinical stage and degree of cell differentiation. Second, the differences between tumors in different parts of the same patient, including heterogeneity between primary and metastatic lesions and heterogeneity between different parts of the same tumor. In addition, tumor heterogeneity also runs through the entire process of tumor evolution in both time and space, showing high complexity and diversity. This heterogeneity originates from the presence of different subtypes of tumor cells in tumor tissues, resulting in differences in gene expression profiles, signal network regulation, mutation spectrum and sensitivity to treatment, leading to differences in sensitivity to different anti-tumor drugs and prognosis and survival. The intratumor heterogeneity of renal cancer is extremely high and has been widely studied. Gerlinger and other scholars first revealed the existence of intratumor heterogeneity in ccRCC through multi-point sampling and high-throughput sequencing of tumor tissues. The study found that 45% of the gene mutations in all sampled specimens were only shared by some tumor specimens, and about 20% of the gene mutations were present in tissue specimens of a single biopsy, indicating that tumor genetics is uneven and regional differences are common in primary ccRCC tumor tissues. Shibata et al. found that there is also heterogeneity between primary cancer and metastatic cancer in patients with advanced ccRCC. Sankin et al. further confirmed the extensive intratumor heterogeneity of ccRCC from the perspective of gene mutations. The study found that various complex genetic branches in tumors are accompanied by more than three mutated genes, especially genes related to tumor evolution. The above studies reveal the existence of extensive tumor heterogeneity in ccRCC from the genomic level, and to a certain extent provide a basis for the screening of targeted drugs, but it is not enough to guide the stratified diagnosis and treatment of patients, and the overall efficacy of targeted drugs is still limited. The reasons are as follows: First, relying on multi-site puncture sequencing cannot cover the entire picture of the tumor, which will greatly underestimate the intratumor heterogeneity; second, genomic analysis mainly targets gene target mutations and copy number variations, while the occurrence and development of tumors is a complex process involving multiple genes and multi-level regulation. Relying solely on genomic information cannot fully reflect the cell phenotype of the tumor, nor can it predict the sensitivity of a certain treatment to a specific patient. Third, due to the continuity of the spatiotemporal evolution and dynamic evolution of tumors, the tumor cell phenotype and genetic mutations change rapidly during the evolution of the disease, leading to acquired drug resistance in patients.

[0004] Therefore, it is necessary to adopt an integrated multi-omics analysis approach to fully understand the tumor heterogeneity of ccRCC, screen and identify prognostic markers, construct an effective ccRCC molecular classification system and prognostic prediction model, and guide the precise treatment strategies and clinical monitoring methods for different ccRCC patients. Summary of the invention

[0005] The purpose of the present application is to provide a reagent for detecting the expression amount of a biomarker for use in preparing a product for evaluating the prognosis of renal cancer, and a kit for evaluating the prognosis of renal cancer.

[0006] This application adopts the following technical solutions:

[0007] The first aspect of the present application discloses the use of a reagent for detecting the expression of a biomarker in the preparation of a product for evaluating the prognosis of renal cancer, wherein the expression includes the expression at the mRNA level and the protein level, and the biomarker includes a first biomarker and / or a second biomarker, wherein the first biomarker includes the following genes: FOS, JUNB, EGR1, NR4A1, IER2, ATF3, and the second biomarker includes at least one of the following genes: SLC16A9, SLC13A1, CYP4A11, ESRRG. It should be noted that in the present application, the expression of the biomarker includes the expression at both the mRNA level and the protein level, and the expression at both levels needs to be upregulated or downregulated at the same time to be able to predict the prognosis of patients with renal cancer.

[0008] In one implementation of the present application, the sample type of the test sample is a renal cancer tissue sample, and the renal cancer is renal clear cell carcinoma.

[0009] In one implementation of the present application, if the expression of the first biomarker is upregulated, the prognosis of renal cancer is poor. It should be noted that the expression level of the first biomarker is the average expression level of each gene in the first biomarker. For each gene in the first biomarker, if all genes are upregulated together, it has a better prognostic value.

[0010] In one implementation of the present application, if the expression of the second biomarker is upregulated, the prognosis of renal cancer is better. It should be noted that the expression level of the second biomarker is the average expression level of each gene in the second biomarker. It should also be noted that for the second biomarker, SLC16A9, SLC13A1, CYP4A11 and ESRRG can also be used as independent predictors to predict the prognosis of patients with renal cancer. For example, if SLC16A9 is upregulated at both the mRNA level and the protein level, it can also be judged that the patient has a good prognosis. For each gene in the second biomarker, if the SLC16A9, SLC13A1, CYP4A11 and ESRRG genes are co-expressed and upregulated, it has a better prediction effect than predicting the prognosis of a single gene.

[0011] In one implementation of the present application, the expression level of the mRNA level of the biomarker is detected by fluorescent quantitative PCR. If the CT value of the biomarker minus the CT value of the internal reference gene is greater than or equal to 1, the biomarker is upregulated at the mRNA level.

[0012] In one implementation of the present application, at least one of the following primer sets is used to perform the fluorescence quantitative PCR detection: FOS upstream primer: 5′-GGGGCAAGGTGGAACAGTTA-3′, FOS downstream primer: 5′-CCTTCAGCAGGTTGGCAAT-3′; JUNB upstream primer: 5′-CCTGGACGATCTGCACAAGA-3′, JUNB downstream primer: 5′-GGTTGGTGTAAACGGGAGGT-3′; EGR1 upstream primer: 5′- CACCTGACCGCAGAGTCTTT-3′, EGR1 downstream primer: 5′-CTGACCAAGCTGAAGAGGGG-3′; NR4A1 upstream primer: 5′-TTCCTGGTGTAAGCTTTGGTATGG-3′, NR4A1 downstream primer: 5′-ACTCTGGATGGACCAACAGG-3′; IER2 upstream primer: 5′-GCCTGAGTTACTTCACCCCC-3′, IER2 downstream primer: 5′-GCTGGAACCTG GGAACCTAC-3′; ATF3 upstream primer: 5′-TTTCAGCACCTTGCCCCAAA-3′, ATF3 downstream primer: 5′-TTGACAAAGGGCGTCAGGTT-3′; SLC6A19 upstream primer: 5′-GTATGTGGCCATCGTGGTCT-3′, SLC6A19 downstream primer: 5′-CAGGTCGAACCCGTTGATGA-3′; SLC13A1 upstream primer: 5′-CCACCTGCTCAGGACAAT GA-3′, SLC13A1 downstream primer: 5′-AAGCTGTTACCGACAGAGGC-3′; CYP4A11 upstream primer: 5′-TCTGGAATCCTCCAAGCGGC-3′, CYP4A11 downstream primer: 5′-AGCAGAGGTCAGGCTGTAGA-3′; ESRRG upstream primer: 5′-CCTACGCTAACACTGTCGCA-3′, ESRRG downstream primer: 5′-TTGGGCATCGAGTTGAGCAT-3′.

[0013] In one implementation of the present application, the expression level of the biomarker at the protein level is detected by immunohistochemistry. If the staining index of the biomarker is greater than 5, the biomarker is upregulated at the protein level. It should be noted that the immunohistochemistry scoring system: staining intensity is 0, negative; staining intensity is 1, low; staining intensity is 2, medium; staining intensity is 3, high. The staining area is 0, 0% staining; the staining area is 1, 1%-25% staining; the staining area is 2, 26%-50% staining; the staining area is 3, 51%-100% staining. Five high-power fields (HP) were randomly selected for evaluation under an optical microscope. "Staining intensity × staining range" is the final score. ≤4 points represent low expression, and 4-9 represents high expression.

[0014] In one implementation of the present application, if the expression levels of the mRNA level and protein level of the first biomarker are respectively higher than the expression levels of the mRNA level and protein level of the second biomarker, the prognosis of renal cancer is poor; if the expression levels of the mRNA level and protein level of the second biomarker are respectively higher than the expression levels of the mRNA level and protein level of the first biomarker, the prognosis of renal cancer is good. It should be noted that if the expression level of the first biomarker is higher than that of the second biomarker, it is judged to be dominated by the first biomarker, and the prognosis of renal cancer is poor; if the expression level of the second biomarker is higher than that of the first biomarker, it is judged to be dominated by the second biomarker, and the prognosis of renal cancer is good.

[0015] The second aspect of the present application discloses a kit for evaluating the prognosis of renal cancer, characterized in that the kit includes a reagent for detecting the expression amount of a biomarker, the biomarker includes a first biomarker and / or a second biomarker, the first biomarker includes the following genes: FOS, JUNB, EGR1, NR4A1, IER2, ATF3, and the second biomarker includes at least one of the following genes: SLC16A9, SLC13A1, CYP4A11, ESRRG.

[0016] In one implementation of the present application, the kit includes a primer set, which is selected from: 5′-GGGGCAAGGTGGAACAGTTA-3′, FOS downstream primer: 5′-CCTTCAGCAGGTTGGCAAT-3′; JUNB upstream primer: 5′-CCTGGACGATCTGCACAAGA-3′, JUNB downstream primer: 5′-GGTTGGTGTAAACGGGAGGT-3′; EGR1 upstream primer: 5′-CACCTGACCGCAGAG TCTTT-3′, EGR1 downstream primer: 5′-CTGACCAAGCTGAAGAGGGG-3′; NR4A1 upstream primer: 5′-TTCCTGGTGTAAGCTTTGGTATGG-3′, NR4A1 downstream primer: 5′-ACTCTGGATGGACCAACAGG-3′; IER2 upstream primer: 5′-GCCTGAGTTACTTCACCCCC-3′, IER2 downstream primer: 5′-GCTGGAACCTGGGAACCTAC- 3′; ATF3 upstream primer: 5′-TTTCAGCACCTTGCCCCAAA-3′, ATF3 downstream primer: 5′-TTGACAAAGGGCGTCAGGTT-3′; SLC6A19 upstream primer: 5′-GTATGTGGCCATCGTGGTCT-3′, SLC6A19 downstream primer: 5′-CAGGTCGAACCCGTTGATGA-3′; SLC13A1 upstream primer: 5′-CCACCTGCTCAGGACAATGA-3′ , SLC13A1 downstream primer: 5′-AAGCTGTTACCGACAGAGGC-3′; CYP4A11 upstream primer: 5′-TCTGGAATCCTCCAAGCGGC-3′, CYP4A11 downstream primer: 5′-AGCAGAGGTCAGGCTGTAGA-3′; ESRRG upstream primer: 5′-CCTACGCTAACACTGTCGCA-3′, ESRRG downstream primer: 5′-TTGGGCATCGAGTTGAGCAT-3′.

[0017] The beneficial effects of this application are:

[0018] In this application, multi-omics analysis methods are integrated to screen and identify prognostic markers, i.e., biomarkers, for renal cancer. The detection of biomarkers can help to judge the prognosis of renal cancer patients, thereby facilitating precise treatment and overall disease management, and improving patient survival. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1This is a schematic diagram of single-cell transcriptome and single-cell chromatin accessibility sequencing analysis of molecular markers and tumor cell clustering of ccRCC tumor epithelial cells.

[0020] Figure 2 This is a schematic diagram of the correlation between the two ccRCC tumor subgroups and patient prognosis and survival, as well as the differences in transcriptional regulatory factors between the two subgroups.

[0021] Figure 3 Figure 2 is the spatial distribution of two ccRCC tumor subpopulations in tumor tissue.

[0022] Figure 4 The receptor ligand pairs and their tissue spatial distribution of the two ccRCC tumor subpopulations for intercellular communication with macrophages or vascular endothelial cells in the tumor microenvironment.

[0023] Figure 5 Schematic diagram of the clinical application efficacy of the combination of four molecular markers for metabolic renal cancer subtypes in the TCGA-ccRCC cohort.

[0024] Figure 6 This is a schematic diagram of the results of separate survival and prognostic analyses using four molecular markers of metabolic renal cell carcinoma subtypes in the TCGA-ccRCC cohort.

[0025] Figure 7 Figure 2 is the ROC curve and nomogram for prognostic analysis using four molecular markers of metabolic renal cell carcinoma subtype in the TCGA-ccRCC cohort. DETAILED DESCRIPTION

[0026] The present invention is further described in detail below by specific embodiments in conjunction with the accompanying drawings. In the following embodiments, many detailed descriptions are intended to enable the present application to be better understood. However, those skilled in the art can effortlessly recognize that some of the features can be omitted in different situations, or can be replaced by other materials and methods. In some cases, some operations related to the present application are not shown or described in the specification, in order to avoid the core part of the present application being overwhelmed by too much description, and for those skilled in the art, it is not necessary to describe these related operations in detail, and they can fully understand the related operations according to the description in the specification and the general technical knowledge in the art.

[0027] In addition, the features, operations or characteristics described in the specification can be combined in any appropriate manner to form various implementations. At the same time, the steps or actions in the method description can also be interchanged or adjusted in a manner that is obvious to those skilled in the art. Therefore, the various sequences in the specification and the drawings are only for the purpose of clearly describing a certain embodiment and are not meant to be a required sequence, unless otherwise specified that a certain sequence must be followed.

[0028] ccRCC is a highly malignant kidney disease and a highly heterogeneous malignant tumor. Precision diagnosis and treatment is an effective way to improve the prognosis and survival of ccRCC patients, and molecular typing is the key to achieving precise diagnosis and treatment of renal cancer. Since the occurrence and development of ccRCC is a multi-stage process, it is affected by a variety of genomic changes, which makes tumor typing and identification very complicated. Research based on a single group technology can only reflect the intrinsic molecular characteristics of the tumor from one perspective and cannot fully reveal the heterogeneity of the tumor.

[0029] In view of this, the present application divides ccRCC tumor cells into metabolic type (low-risk group) and stress type (high-risk group) based on sequencing analysis of different levels of ccRCC, such as single-cell transcriptome, epigenome and spatial transcriptome, and identifies and screens molecular markers of two different subtypes. On this basis, the value of metabolic molecular marker combination in predicting low-risk classification and better prognosis of ccRCC patients is verified through TCGA big data, and its reliability as the current classification diagnosis of renal clear cell carcinoma is verified through various other experimental methods. The present application discloses the application of stress marker combination and metabolic marker combination in renal clear cell carcinoma as potential targets for molecular classification diagnosis of renal clear cell carcinoma.

[0030] The present application is further described in detail below by specific examples. The following examples are only further described for the present application and should not be construed as limiting the present application. In the present example, unless otherwise specified, the reagents and instruments used are all commercially available, and the experimental operations are carried out in accordance with the product instructions and conventional experimental specifications.

[0031] 1. Screening of molecular markers: By integrating single-cell multi-omics technologies such as scRNA-seq and scATAC-seq of the same cell, as well as spatial transcriptome sequencing of the same tissue, the heterogeneity of normal kidney tissue, low-stage and high-stage ccRCC was comprehensively analyzed, and the transcriptome and chromatin accessibility characteristics of ccRCC cells were analyzed. Figure 1 This is a schematic diagram of the molecular markers and tumor cell clustering of ccRCC tumor epithelial cells analyzed by single-cell transcriptome and single-cell chromatin accessibility sequencing. Figure 1In the figure, A. (a) shows scRNA-seq UMAP showing the RNA expression of CA9 in all non-tumor cells and tumor cells from ccRCC samples. A. (b) shows scRNA-seq and scATAC-seq UMAP showing malignant epithelial cells of 4 ccRCC samples after batch effect removal; B. The dot plot shows the average RNA expression (upper figure) and gene activity level (lower figure) of the screened marker genes; C. shows that all tumor cells in ccRCC are grouped according to the screened marker genes, and different colors represent tumor cells belonging to different groups; D. The functional enrichment analysis diagram shows the enriched pathways of each subgroup, the color of the point represents the P value after FDR correction, and the size of the point represents the number of genes in each pathway, highlighting the main enriched pathways of the "metabolic subgroup". In the analysis of tumor epithelial cells, we screened out a combination of molecular markers for characterizing two different ccRCC subgroups, namely, stress markers represented by FOS: FOS, JUNB, EGR1, NR4A1, IER2 and ATF3; metabolic markers represented by SLC16A9: SLC16A9, SLC13A1, CYP4A11 and ESRRG. Based on multi-omics data analysis, we identified two risk subtypes of ccRCC, namely the low-risk group Tumor_SLC16A9 and the high-risk group Tumor_FOS. Unlike previous studies, this study fully revealed the different characteristics between the two tumor subgroups from multiple dimensions. For example, in terms of function, Tumor_SLC16A9 is mainly enriched in metabolic pathways of various energy substances, so it is named metabolic type; while the main functions of the Tumor_FOS subtype are enriched in signal pathways related to external interactions such as oxidative stress response and immune regulation, so it is named stress type. Specifically, it includes:

[0032] 1. Tissue Isolation and Cell Nuclei Isolation and Bank Construction

[0033] Cancer tissue and normal kidney tissue from patients with renal cancer were collected, and fresh samples were frozen in liquid nitrogen and stored at -80°C. Dissociation of nuclei was performed entirely on ice. 20 mg of frozen tissue was mixed with a loose stirring bar in 2 mL of frozen homogenization buffer (0.25 M sucrose, 25 mM KCl, 5 mM MgCl2, 20 mM Tricine-KOH, pH 7.8) with 0.1% NP40, 1 mM DTT, 0.15 mM spermine, 0.5 mM spermidine, 1 u / mL RNase inhibitor and EDTA-free protease inhibitor. The homogenized tissue was filtered with a 40 μm filter, centrifuged at 350 g for 5 minutes, and all supernatant was removed. Subsequently, 400 ul of homogenization buffer was added to the nuclei, the nuclei were gently resuspended, mixed with an equal volume of 50% ethanol density medium, and centrifuged at 5000 g in a 4°C centrifuge for 20 minutes. The nuclei were collected and transferred to pre-cooled tubes for counting. Then 500,000 counted nuclei were transferred to a tube containing 1 ml of wash buffer (RSB: 10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.1% BSA and 1 U / ml RNase inhibitor in water) containing 0.1% Tween-20. Centrifuge at 500 g for 10 minutes in a pre-cooled (4°C) centrifuge. The nuclei were resuspended in frozen diluted nuclei buffer (provided by 10X Genomics, PN-1000283) and then immediately subjected to ChromiumNext GEM "scATAC-seq and scRNA-seq" (CG000338) for single-cell multi-omics sequencing.

[0034] 2. Preparation of Visium Spatial Transcriptome Sequences

[0035] Renal cell carcinoma tissue was placed under optimal cutting temperature (OCT, Tissue-Tek) and frozen on dry ice. The tissue was cut into 10-μm-thick tissue sections and stained with hematoxylin and eosin (H&E). Subsequently, the pathologist evaluated and identified the relevant areas of the tissue and selected these areas for further analysis. Tissue optimization and spatial gene expression were performed as described by 10xGenomics (https: / / 10xgenomics.com / ) using H&E as a counterstain. Imaging was performed on an Olympus vs120 scanner. mRNA library preparation and sequencing (IlluminaNova) were performed at BerryGenomics.

[0036] 3. Multi-omics data processing

[0037] Initial processing of scMutiome data used the Cell Ranger ARC Pipeline (https: / / support.10xgenomics.com / single-cell-multiome-atac-gex / software / pipelines / latest / what-is-cell-ranger-arc) by running cellranger-arc count with default settings to perform alignment, filtering, barcode counting, peak calling, and ATAC and RNA molecule counting. Subsequent datasets were processed using Seurat and Signac. The filtered_feature_bc_matrix generated by Cell RangerARC was read into R using the Seurat function Read10X_h5. DoubletFinder was run on each sample to remove doublets before further analysis. To this end, cells were log-normalized and the top 2000 variable genes were selected for principal component analysis (PCA) for dimensionality reduction. The top 20 principal components were retained and clustered at a resolution of 0.5 with a recombination rate set to 0.2. After running DoubletFinder, the remaining cells from all samples were merged into a single Seurat object, and cells with nFeature_RNA / cell greater than 7500, nCount_RNA / cell greater than 25000, mitochondrial RNA greater than 15%, or nCount_RNA / cell less than 1000 were removed. The remaining cells from all samples after scRNA quality control were then loaded into Signac. Low-quality cells (nFeature_ATAC<500, nFeature_ATAC>25,000, nCount_ATAC<1,000, peakregion fragments>50,000, peakregion fragments<1,000, nucleosome signal>2or TSS enrichment<1) were further removed. After quality control, 73,477 cells remained for downstream analysis.

[0038] 4. scRNA-seq Data Analysis

[0039] scRNA-seq data were normalized using “NormalizeData”. Integrating multiple samples is essential to improve statistical power and detect subtle differences between experimental groups. Canonical correlation analysis (CCA) was performed on 6 different samples using the Seurat software package. We selected the top 2000 highly variable genes and used PCA to reduce the dimensionality of the data. To combine data from multiple samples and overcome batch effects, principal components were then calculated on the scaled data and UMAP was generated from the resulting 30 pcs. Clusters were identified by the Seurat functions findneighbors and FindClusters with a resolution of 1. The expression of marker genes in the resulting clusters was then used for downstream analyses described in the results of the labeled clusters. For the non-tumor kidney clusters, cells from two normal samples were integrated using the CCA method. Clusters were then identified using the Seurat functions findneighbors and FindClusters with a resolution of 0.5. The expression of marker genes in the resulting clusters was then used to label the clusters. To further resolve subpopulations within the samples, we performed subclustering analysis of epithelial cells, immune cells, and endothelial cells in the integrated dataset of the six samples. We used the integrated dataset and performed dimensionality reduction using the first 15 principal components and clustering at a resolution of 1. For the analysis of PT cells, two non-tumor kidney samples were integrated using the CCA method. We selected the top 2000 variable genes and performed dimensionality reduction using principal component analysis. The top 30 principal components were retained and clustered at a resolution of 0.5.

[0040] 5. scATAC-seq Data Analysis

[0041] For each sample, the fragment file generated by Cell Ranger was imported into MACS2. The peaks for each sample were then combined to generate all intersecting peaks. Finally, a file containing all peaks in the sample was constructed for further analysis. The cells were imported into Signac (https: / / stuartlab.org / signac / articles / overview) to process the scATAC data. First, the peak-by-peak matrix and fragment file created by Cell-Ranger were imported. For data integration, a narrow peak file containing all intersecting peaks is essential to cover the peak positions in each sample. To filter out low-quality cells in the 6 samples, a threshold of 1000 was set. <nCount_ATAC<50000,nucleosome_signal<2,TSS.enrichment> 1 to remove outliers and cells that are degrading. Then, Signac was used to perform data normalization and dimensionality reduction.

[0042] (1) Sample integration: For the integration of all cells from the six samples, reciprocal LSI projection was used to find the integration anchor by using dimensions ranging from 2 to 30. After merging the six samples and calculating the LSI embedding, the low-dimensional cell embeddings in the merged dataset were integrated in 1 to 30 dimensions. After normalization and dimensionality reduction of the data, visualization was achieved using graph-based clustering and nonlinear dimensionality reduction. Two-dimensional UMAP plots were generated using Louvain clustering and UMAP reduction in 2 to 30 dimensions. For other cell type subsets, the integration method was similar to the integration method for all cells in the six samples mentioned above.

[0043] (2) Mapping cell type labels from scRNA to scATAC: Thanks to the advantages of single-cell multi-omics technology, scRNA and scATAC libraries share the same cell barcoding system, and the cell types determined by scRNA analysis can be directly projected into scATAC cells.

[0044] (3) Peak-gene link identification: In order to identify potential regulatory relationships between transcription factors and their target genes, the correlation between chromatin accessibility and gene expression was analyzed. After calculating the GC content of each peak in the hg38 reference, the correlation between scRNA gene expression and the chromosomal accessibility of nearby peaks in scATAC was calculated. For each gene, open chromatin peak regions within 125 kb upstream or downstream of the transcription start site were considered, excluding promoter regions. Highly correlated and positively correlated links were focused on, and biases caused by GC content, overall accessibility, and peak size were corrected. Links can be visualized by using the "CoveragePlot" function.

[0045] (4) Gene activity score calculation: The fragments generated by scATAC can be used to simulate gene expression. The extracted fragments range from 2kb upstream of the gene promoter to the terminal gene body. Then, the number of fragments per cell is calculated to create a gene activity score. Finally, a cellular gene activity score matrix is ​​obtained.

[0046] (5) Calculate differential peaks of specific cell types: In the FindMarkers function, differential peaks of specific cell types can be obtained. It uses logistic regression to perform differential accessibility tests. In order to improve calculation efficiency, the minimum proportion of detected genes is 5%.

[0047] 6. Obtain two sets of molecular markers through sequencing results

[0048] A total of 33,987 tumor epithelial cells from all tumor samples were selected and batch corrected for subsequent analysis of tumor cell intrinsic differential key gene signatures. Considering the heterogeneity between patients, the differentially expressed genes within each patient's tumor were first analyzed, and then 10 differentially expressed genes co-expressed between four patients were identified. The 10 degs were further divided into three different gene signatures based on gene expression patterns and biological functions. The FOS_signature is characterized by "early stress response" transcription factors, including FOS (one of the earliest and most characterized immediate early genes), JUNB (heterodimer with FOS), NR4A1 (also known as early response protein NAK1), IER2 (immediate early response 2), EGR1 (early growth response 1), and ATF3 (activating transcription factor 3). SLC16A9_signature consisted of metabolism-related genes, including SLC16A9 (monocarboxylate transporter 9), SLC13A1 (renal sodium / sulfate co-transporter), ESRRG (estrogen-related receptor gamma), and CYP4A11 (long-chain fatty acid-mega-monooxygenase).

[0049] Based on the RNA expression of the signature genes, tumor cells were divided into 2 types, namely, stress-type Tumor_FOS and metabolic-type Tumor_SLC16A9. The obvious differential expression pattern of the marker genes demonstrated the specificity of tumor subpopulation assignment. Similarly, the scATAC portion of the data was analyzed, and it was found that the clustered scATAC-seq tracks represented differential chromatin accessibility peaks of the marker genes, which could also distinguish the identity of each tumor subtype. The reliability of the subtype definition based on gene signatures was further verified in other independent ccRCC scRNA-seq cohorts, in which there was obvious clustering of tumor slc16a9 cells and specific expression of tumor slc16a9 markers. Functional enrichment analysis was then performed based on the differentially expressed genes of each tumor subtype. The results showed that the biological processes of stress-type Tumor_FOS were cell adhesion, response to hypoxia or extracellular stimulation, and regulation of immune cells. Metabolic-type Tumor_SLC16A9 cells were associated with fatty acid / carboxylic acid / amino acid metabolic processes.

[0050] 2. Performance Verification of Molecular Markers

[0051] In order to determine the clinical significance of tumor subtypes obtained from single cells in the cohort, survival analysis was performed using the big data TCGA ccRCC data, and it was found that high expression of the Tumor_FOS feature predicted a poor prognosis, while high expression of Tumor_SLC16A9 levels was associated with better overall survival in ccRCC patients. In addition, the ssGSEA enrichment score of Tumor_SLC16A9 was significantly higher in early-stage than in late-stage ccRCC patients. Similarly, the Tumor_SLC16A9 feature score was significantly higher in non-metastatic tumors than in metastatic tumors, indicating that Tumor_SLC16A9 represents a specific ccRCC subtype with a lower grade and better prognosis. Specifically:

[0052] Figure 2 This is a schematic diagram of the correlation between the two ccRCC tumor subgroups and patient prognosis and survival, as well as the differences in transcriptional regulatory factors between the two subgroups. Figure 2 In the figure, A. represents KM survival analysis based on TCGA-ccRCC data; B. represents single-cell transcriptome and single-cell chromatin accessibility sequencing analysis of the regulated transcription factors of the two tumor subpopulations. Figure 3 This is the spatial distribution map of two ccRCC tumor subpopulations in tumor tissue. Figure 3 In the figure, the enrichment of the activity of the fat metabolism pathway (Adipogenesis) is also shown, where the boundaries of the cell clusters are marked with dotted lines. Figure 4 The receptor ligand pairs and their tissue spatial distribution of the two ccRCC tumor subpopulations for intercellular communication with macrophages or vascular endothelial cells in the tumor microenvironment. Figure 5 This is a schematic diagram of the clinical application efficacy of the combination of four molecular markers for metabolic renal cancer subtypes in the TCGA-ccRCC cohort. Figure 5 In the figure, A. indicates that in ccRCC samples from TCGA, the comprehensive expression level of metabolic renal cancer subtype molecular markers is high, which is significantly positively correlated with early ccRCC tumor pathological stage and tumor metastasis. The vertical axis of the violin plot shows the ssGSEA enrichment score of each group. B. indicates that the transcriptomic analysis of tumor biopsy tissues of ccRCC immunotherapy responders and non-responders showed that there was a significant high expression of metabolic renal cancer subtype molecular markers between ccRCC anti-PD1 immunotherapy responders and non-responders.

[0053] Combined with the transcriptome data analysis of 532 TCGA-ccRCC patients, it was found that the up-regulated expression level of Tumor_FOS subtype molecular markers in tumor tissues was significantly correlated with the poor prognosis of patients, while the increased expression of Tumor_SLC16A9 subtype molecular markers was significantly correlated with the good prognosis and survival of ccRCC patients ( Figure 2); In addition, the transcription factors regulated by the two subtypes are also very different. In terms of spatial distribution, the stress subtype Tumor_FOS is dispersed along the outside of the tumor tissue, highly integrated with stromal cells and immune cells, and the boundary is not clear ( Figure 3 ), and by secreting immune and inflammatory cytokines, they interact with T cells, macrophages or vascular endothelial cells in the microenvironment, triggering inflammation and angiogenesis, thereby driving tumor metastasis and invasion ( Figure 4 ); The metabolic subgroup Tumor_SLC16A9 is spatially concentrated in the core area of ​​the tumor tissue, with less immune cell infiltration and a clear boundary with the matrix composed of fibroblasts ( Figure 3 ), and in terms of communication with tumor microenvironment cells, it promotes the adaptation of tumor cells to the microenvironment by regulating molecular interactions such as extracellular matrix remodeling ( Figure 4 ). In addition, it was found that the high expression of metabolic Tumor_SLC16A9 subgroup molecular markers was not only significantly positively correlated with low tumor grade and non-metastatic tumors in ccRCC ( Figure 5 ), and was also significantly positively correlated with the high response rate of PD1 immunotherapy in ccRCC ( Figure 5 ).

[0054] Figure 6 This is a schematic diagram of the results of separate survival and prognostic analyses using four genes of metabolic renal cancer subtype molecular markers in the TCGA-ccRCC cohort. Figure 6 In the data, the four metabolic subtype ccRCC molecular markers can be used as independent predictors of ccRCC prognosis. A. indicates that the survival analysis of the four metabolic renal cancer subtype molecular markers in the TCGA-ccRCC cohort showed that the high expression of each molecular marker was significantly positively correlated with the patient's overall survival prognosis (OS). B. indicates that the high expression of each molecular marker was significantly positively correlated with better disease-specific prognosis (DSS) survival. Figure 7 Figure 2 is the ROC curve and nomogram for prognostic analysis using four molecular markers of metabolic renal cell carcinoma subtype in the TCGA-ccRCC cohort. Figure 7It was obtained using the two most commonly used prognostic model construction methods. On the one hand, the "rms" and "survival" packages in the R.4.1.2 software were used to construct the Cox survival nomogram model. The proportional hazard regression model (Cox regression model) is a semi-parametric regression model that can be used to describe the impact of multiple characteristics over time on mortality at a certain time. It is a commonly used and important prognostic survival risk prediction model, which can be expressed as: h(t|X)=h0(t)*exp(β1x1+β2x2+...+βnxn). The nomogram survival model (Nomogram) is a visualization based on the Cox regression model. First, we will score each influencing factor in the Cox regression model according to its contribution to the prognosis of ccRCC patients. Secondly, we will add up each score to get the total score. Finally, the function between the total score and the prognosis survival of ccRCC patients is transformed to calculate the predicted value of the individual's prognosis. Figure 7 The diagnostic accuracy of the model was evaluated by drawing the receiver operator characteristic (ROC) curve. The area under the ROC curve (AUC) was greater than 0.5, which proved that the diagnostic model had a certain diagnostic value. At the same time, the closer the AUC is to 1, the better the authenticity of the diagnostic test. The Hosmer-Lemeshow (HL) goodness-of-fit test evaluated the fitting effect of the model. If the P value is greater than 0.05, it means that the HL test is passed, which means that there is no significant difference between the predicted value and the true value. On the contrary, if the P value is less than 0.05, it means that the HL test is not passed, and there is a significant difference between the predicted value and the true value, which means that the model fit is poor and the diagnosis cannot be made based on this model. The calibration curve is drawn to determine the gap between the model predicted value and the true value. After 1000 Bootstrap self-sampling, the calibration curve of the model is drawn. The calibration curve is a scatter plot of the actual incidence and the predicted incidence.

[0055] In the TCGA-ccRCC database, metabolic molecular markers were subjected to Kaplan-Meier prognostic analysis. The results showed that the four metabolic ccRCC molecular markers SLC16A9, SLC13A1, CYP4A11 and ESRRG can be used as independent predictors of ccRCC prognosis, and the high expression of each gene is significantly positively correlated with the patient's overall survival prognosis (OS) and disease-specific prognosis (DSS) ( Figure 6). Since a single gene or a single indicator has limited value in explaining tumor heterogeneity and complexity, the combination of multiple indicators can reflect more dimensional information. In order to further construct a prognostic prediction model based on molecular markers of single-cell multi-omics sequencing, this example incorporates four ccRCC metabolic molecular markers to construct a prediction model, and verifies the comprehensive predictive value of metabolic molecular markers for OS and DFS of patients through ROC curves, and calculates the specificity and sensitivity of the prediction model. The results are shown in Figure 7 As shown in the figure, the low-risk group prediction model based on single-cell multi-omics has an area under the curve (AUC) above 0.5; nomogram analysis shows that compared with the single-omics model, the model built by integrating multi-omics can better predict tumor grade ( Figure 7 ).

[0056] Therefore, this example conducts in-depth research on ccRCC through single-cell multi-omics, which not only analyzes the spatiotemporal heterogeneity of ccRCC in multiple dimensions such as gene expression levels, regulatory mechanisms and tissue distribution, but also screens and obtains molecular markers of two different tumor subgroups, metabolic type (low-risk group) and stress type (high-risk group), and reveals its potential translational application value in terms of patient prognosis and survival.

[0057] 3. Application of Molecular Markers:

[0058] RT-PCR test:

[0059] The sample kidney tissue was taken and the RNA of the kidney tissue was extracted; the sample kidney tissue RNA was reverse transcribed to obtain the sample kidney tissue cDNA; the kidney tissue cDNA was used as a template and the following primer pairs were used to perform RT-PCR reaction, and the mRNA expression levels (CT values) of the genes FOS, JUNB, EGR1, NR4A1, IER2 and ATF3, SLC16A9, SLC13A1, CYP4A11 and ESRRG in the sample kidney tissue were subtracted from the mRNA expression level (CT value) of the internal reference gene β-actin to obtain the ΔCT value. When the ΔCT values ​​of the mRNA expression levels of the target genes in the sample were all greater than 1, it was judged to be highly expressed. The primer pairs are as follows:

[0060] FOS upstream primer: 5′-GGGGCAAGGTGGAACAGTTA-3′ (SEQ ID NO. 1);

[0061] FOS downstream primer: 5′-CCTTCAGCAGGTTGGCAAT-3′ (SEQ ID NO. 2);

[0062] JUNB upstream primer: 5′-CCTGGACGATCTGCACAAGA-3′ (SEQ ID NO. 3);

[0063] JUNB downstream primer: 5′-GGTTGGTGTAAACGGGAGGT-3′ (SEQ ID NO. 4);

[0064] EGR1 upstream primer: 5′-CACCTGACCGCAGAGTCTTT-3′ (SEQ ID NO. 5);

[0065] EGR1 downstream primer: 5′-CTGACCAAGCTGAAGAGGGG-3′ (SEQ ID NO. 6);

[0066] NR4A1 upstream primer: 5′-TTCCTGGTGTAAGCTTTGGTATGG-3′ (SEQ ID NO. 7);

[0067] NR4A1 downstream primer: 5′-ACTCTGGATGGACCAACAGG-3′ (SEQ ID NO. 8);

[0068] IER2 upstream primer: 5′-GCCTGAGTTACTTCACCCCC-3′ (SEQ ID NO. 9);

[0069] IER2 downstream primer: 5′-GCTGGAACCTGGGAACCTAC-3′ (SEQ ID NO. 10);

[0070] ATF3 upstream primer: 5′-TTTCAGCACCTTGCCCCAAA-3′ (SEQ ID NO. 11);

[0071] ATF3 downstream primer: 5′-TTGACAAAGGGCGTCAGGTT-3′ (SEQ ID NO. 12);

[0072] SLC6A19 upstream primer: 5′-GTATGTGGCCATCGTGGTCT-3′ (SEQ ID NO. 13);

[0073] SLC6A19 downstream primer: 5′-CAGGTCGAACCCGTTGATGA-3′ (SEQ ID NO. 14);

[0074] SLC13A1 upstream primer: 5′-CCACCTGCTCAGGACAATGA-3′ (SEQ ID NO. 15);

[0075] SLC13A1 downstream primer: 5′-AAGCTGTTACCGACAGAGGC-3′ (SEQ ID NO. 16);

[0076] CYP4A11 upstream primer: 5′-TCTGGAATCCTCCAAGCGGC-3′ (SEQ ID NO. 17);

[0077] CYP4A11 downstream primer: 5′-AGCAGAGGTCAGGCTGTAGA-3′ (SEQ ID NO. 18);

[0078] ESRRG upstream primer: 5′-CCTACGCTAACACTGTCGCA-3′ (SEQ ID NO. 19);

[0079] ESRRG downstream primer: 5′-TTGGGCATCGAGTTGAGCAT-3′ (SEQ ID NO. 20).

[0080] RT-PCR reaction system: 10 μL of SYBR Green I Master Mix (Life Technologies), 0.5 μL of 5 U / μL DNA polymerase, 0.5 μL of 10 μM primer set and 5 ng of DNA template were mixed, and the remainder was supplemented with RNAse-free Water to prepare 20 μL of PCR amplification reaction solution.

[0081] Temperature conditions for RT-PCR: 50°C for 2 minutes, 95°C for 2 minutes, 1 cycle; 95°C for 15 seconds, 55°C for 30 seconds, 72°C for 40 seconds, 40 cycles.

[0082] Result analysis: The mRNA expression level of each gene is expressed by the difference (ΔCT) between the CT value of the amplification curve of the gene and the CT value of the amplification curve of the internal reference gene β-actin, and the mRNA expression level of a group of markers is expressed by the average value of the mRNA expression level of each gene. Thus, the mRNA expression level of each group of biomarkers is obtained.

[0083] HE staining and immunohistochemistry (IHC) staining of tissue sections:

[0084] The ccRCC tissue blocks were cut into slices of about 4-6 μm thick using a paraffin slicer, and then placed in a 65-70°C constant temperature baking tray for 35-55 minutes. The baked paraffin slices were then stained with HE. The staining process included dewaxing, nuclear staining and cytoplasmic staining with Hematoxylin and Eosin, and dehydration. The dewaxing time was adjusted appropriately according to the temperature conditions. Finally, the slices were transparentized with xylene, and the slices transparentized with xylene were sealed with neutral resin. The tissue structure and tumor cell morphology and differentiation were observed under a microscope.

[0085] ccRCC tissue sections without necrosis or defects in the tumor area were selected for HE staining and observed under a microscope. After dewaxing and hydration, EDTA high-temperature and high-pressure antigen repair was performed. A 1:50 EDTA repair solution was prepared, placed in a pressure cooker and heated to boil on an induction cooker. The sections were placed in the repair solution. After the repair was completed and naturally cooled, peroxidase inhibitors were added. The sections were incubated at room temperature for 10-15 minutes. After rinsing with PBS three times, goat serum working solution was added for blocking for 10-15 minutes. The supernatant was then poured out, and the diluted primary antibodies (FOS, JUNB, EGR1, NR4A1, IER2, ATF3, SLC16A9, SLC13A1, CYP4A11 and ESRRG) were added to different consecutive tissue sections of the same patient and incubated in a constant temperature incubator at 37°C for 1 hour. After rinsing, add the secondary antibody working solution and incubate at room temperature for 15 minutes. After rinsing the secondary antibody, add DAB for 3-5 minutes for color development, and then counterstain with hematoxylin. Followed by alcohol differentiation, blueing, dehydration, transparency, and neutral resin sealing, observe the antibody signal expression and cell nuclear staining under a microscope.

[0086] The protein expression levels of different molecular markers (FOS, JUNB, EGR1, NR4A1, IER2, ATF3, SLC16A9, SLC13A1, CYP4A11 and ESRRG) stained in tissues were determined by integrating the signal intensity and expression area of ​​IHC staining. The cell staining intensity was scored into 4 levels: 0 for no staining, 1 for light yellow, 2 for brownish yellow, and 3 for brownish brown; the cell staining area was scored into 5 levels: 0 for positive cells <5%, 1 for 5%-25%, 2 for 26%-50%, 3 for 51%-75%, and 4 for >75%. The multiplication of the staining intensity and the staining area score was the expression level of the molecular marker in the tissue. A staining index of ≤4 points represented low expression, and 4-9 points represented high expression. The protein expression of a group of markers was expressed by the average of the IHC scores of each gene, thereby obtaining the protein expression of each group of biomarkers.

[0087] Test results:

[0088] According to the mRNA expression value and IHC score in the renal cancer tumor samples after surgery, the average score of the two groups of markers for each patient was calculated. If the score of the first biomarker (FOS, JUNB, EGR1, NR4A1, IER2, ATF3) is higher than that of the second biomarker (SLC16A9, SLC13A1, CYP4A11, ESRRG), the patient is judged to be the type dominated by the first biomarker, and the prognosis of renal cancer is poor; if the score of the second biomarker is higher than that of the first biomarker, the patient is judged to be the type dominated by the second biomarker, and the prognosis of renal cancer is good.

[0089]

[0090]

[0091] From the above, it can be seen that the use of the two groups of biomarkers in this embodiment to detect the expression levels of the patient's mRNA and protein levels can accurately predict the prognosis of patients with renal cancer. The high expression of the mRNA and protein levels of the first biomarker is associated with a higher pathological grade, a larger lesion, a higher disease stage and a shorter survival period, and a poor prognosis; the high expression of the mRNA and protein levels of the second biomarker is associated with a lower pathological grade, a smaller lesion, a lower disease stage and a longer survival period, and a better prognosis.

[0092] The above contents are further detailed descriptions of the present application in combination with specific implementation methods, and it cannot be determined that the specific implementation of the present application is limited to these descriptions. For ordinary technicians in the technical field to which the present application belongs, several simple deductions or substitutions can be made without departing from the concept of the present application.

Claims

1. Use of a reagent for detecting the expression of a biomarker in the preparation of a product for evaluating the prognosis of renal cancer, characterized in that: The expression amount includes the expression amount at the mRNA level and the protein level, the biomarker includes a first biomarker and / or a second biomarker, the first biomarker includes the following genes: FOS, JUNB, EGR1, NR4A1, IER2, ATF3, and the second biomarker includes at least one of the following genes: SLC16A9, SLC13A1, CYP4A11, ESRRG.

2. The use according to claim 1, characterized in that: The sample type of the test sample is a renal cancer tissue sample, and the renal cancer is renal clear cell carcinoma.

3. The use according to claim 1, characterized in that: If the expression of the first biomarker is upregulated, the prognosis of renal cancer is poor.

4. The use according to claim 1, characterized in that: If the expression of the second biomarker is upregulated, the prognosis of renal cancer is better.

5. The use according to any one of claims 1 to 4, characterized in that: The expression level of the mRNA level of the biomarker is detected by fluorescent quantitative PCR. If the CT value of the biomarker minus the CT value of the internal reference gene is greater than or equal to 1, the expression of the biomarker at the mRNA level is upregulated.

6. The use according to claim 1, characterized in that: The method comprises using at least one of the following primer sets to perform the detection by the fluorescent quantitative PCR method: FOS upstream primer: 5′-GGGGCAAGGTGGAACAGTTA-3′, FOS downstream primer: 5′-CCTTCAGCAGGTTGGCAAT-3′; JUNB upstream primer: 5′-CCTGGACGATCTGCACAAGA-3′, JUNB downstream primer: 5′-GGTTGGTGTAAACGGGAGGT-3′; EGR1 upstream primer: 5′-CACCTGACCGCAGAGTCTTT-3′, EGR1 downstream primer: 5′-CTGACCAAGCTGAAGAGGGG-3′; NR4A1 upstream primer: 5′-TTCCTGGTGTAAGCTTTGGTATGG-3′, NR4A1 downstream primer: 5′-ACTCTGGATGGACCAACAGG-3′; IER2 upstream primer: 5′-GCCTGAGTTACTTCACCCCC-3′, IER2 downstream primer: 5′-GCTGGAACCTGGGAACCTAC-3′; ATF3 upstream primer: 5′-TTTCAGCACCTTGCCCCAAA-3′, ATF3 downstream primer: 5′-TTGACAAAGGGCGTCAGGTT-3′; SLC6A19 upstream primer: 5′-GTATGTGGCCATCGTGGTCT-3′, SLC6A19 downstream primer: 5′-CAGGTCGAACCCGTTGATGA-3′; SLC13A1 upstream primer: 5′-CCACCTGCTCAGGACAATGA-3′, SLC13A1 downstream primer: 5′-AAGCTGTTACCGACAGAGGC-3′; CYP4A11 upstream primer: 5′-TCTGGAATCCTCCAAGCGGC-3′, CYP4A11 downstream primer: 5′-AGCAGAGGTCAGGCTGTAGA-3′; ESRRG upstream primer: 5′-CCTACGCTAACACTGTCGCA-3′, ESRRG downstream primer: 5′-TTGGGCATCGAGTTGAGCAT-3′.

7. The use according to claim 5, characterized in that: The expression level of the biomarker at the protein level is detected by immunohistochemistry. If the staining index of the biomarker is greater than 5, the biomarker is up-regulated at the protein level.

8. The use according to claim 7, characterized in that: If the expression levels of the mRNA level and protein level of the first biomarker are respectively higher than the expression levels of the mRNA level and protein level of the second biomarker, the prognosis of renal cancer is poor; if the expression levels of the mRNA level and protein level of the second biomarker are respectively higher than the expression levels of the mRNA level and protein level of the first biomarker, the prognosis of renal cancer is good.

9. A kit for evaluating the prognosis of renal cancer, characterized in that: The kit includes reagents for detecting the expression amount of biomarkers, and the biomarkers include a first biomarker and / or a second biomarker, the first biomarker includes the following genes: FOS, JUNB, EGR1, NR4A1, IER2, ATF3, and the second biomarker includes at least one of the following genes: SLC16A9, SLC13A1, CYP4A11, ESRRG.

10. The kit according to claim 9, characterized in that The kit comprises a primer set, and the primer set is selected from: FOS upstream primer: 5′-GGGGCAAGGTGGAACAGTTA-3′, FOS downstream primer: 5′-CCTTCAGCAGGTTGGCAAT-3′; JUNB upstream primer: 5′-CCTGGACGATCTGCACAAGA-3′, JUNB downstream primer: 5′-GGTTGGTGTAAACGGGAGGT-3′; EGR1 upstream primer: 5′-CACCTGACCGCAGAGTCTTT-3′, EGR1 downstream primer: 5′-CTGACCAAGCTGAAGAGGGG-3′; NR4A1 upstream primer: 5′-TTCCTGGTGTAAGCTTTGGTATGG-3′, NR4A1 downstream primer: 5′-ACTCTGGATGGACCAACAGG-3′; IER2 upstream primer: 5′-GCCTGAGTTACTTCACCCCC-3′, IER2 downstream primer: 5′-GCTGGAACCTGGGAACCTAC-3′; ATF3 upstream primer: 5′-TTTCAGCACCTTGCCCCAAA-3′, ATF3 downstream primer: 5′-TTGACAAAGGGCGTCAGGTT-3′; SLC6A19 upstream primer: 5′-GTATGTGGCCATCGTGGTCT-3′, SLC6A19 downstream primer: 5′-CAGGTCGAACCCGTTGATGA-3′; SLC13A1 upstream primer: 5′-CCACCTGCTCAGGACAATGA-3′, SLC13A1 downstream primer: 5′-AAGCTGTTACCGACAGAGGC-3′; CYP4A11 upstream primer: 5′-TCTGGAATCCTCCAAGCGGC-3′, CYP4A11 downstream primer: 5′-AGCAGAGGTCAGGCTGTAGA-3′; ESRRG upstream primer: 5′-CCTACGCTAACACTGTCGCA-3′, ESRRG downstream primer: 5′-TTGGGCATCGAGTTGAGCAT-3′.

Citation Information

Cited By

  • Single cell data quality control processing method and system

    CN119920311A

  • A method and system for single-cell data quality control processing

    CN119920311B